J&J
J&J’s Invokana becomes first FDA-approved oral diabetes drug to reduce cardiovascular event risk
October 31, 2018Research and Development, Sales and Marketing FDA, J&J, JJ, invokana, pharma
The FDA has given the go-ahead for Johnson & Johnson’s drug Invokana (canagliflozin) for use in the risk reduction of …
US court overturns J&J’s Zytiga patent in combination with prednisone
October 29, 2018Sales and Marketing J&J, JJ, Johnson and Johnson, Zytiga, court, generic, prednisone
A court in New Jersey has invalidated Johnson & Johnson’s patent on the prostate cancer drug Zytiga when used in …
Top Ten most popular articles on Pharmafile.com this week!
October 26, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, GSK, HDA, J&J, JJ, brexit, clinical trials, pharmafile, resutls, stockpiling, top 10
Winter is coming! And with it an assortment of promising and not so promising results from big pharma. While J&J …
J&J announce promising Phase 1/2a results for HIV vaccine
October 23, 2018Manufacturing and Production AIDS, HIV, J&J, JJ, Vaccine, infectious diseases
The world may be one step closer to discovering a preventative vaccine for HIV following American multinational Johnson & Johnson’s …
GSK named third best UK workplace
October 22, 2018Sales and Marketing AbbVie, Amgen, BMS, Eli Lilly, GSK, J&J, JJ, work
British multinational GlaxoSmithKline has been rated as the third best company to work for in the UK, according to jobs …
J&J pledges to end global TB pandemic
September 25, 2018Manufacturing and Production J&J, JJ, Johnson and Johnson, TB, access, tuberculosis
Johnson and Johnson have announced that they are launching a 10-year initiative aimed at helping to end tuberculosis, the world’s …
Europe approves Janssen’s Darzalex in frontline multiple myeloma
September 4, 2018Manufacturing and Production, Research and Development, Sales and Marketing EU, Europe, J&J, JJ, Janssen, darzalex, multiple myeloma, pharma
Janssen has revealed that its CD38-targeting biologic drug Darzalex (daratumumab) has received approval from the European Commission, authorising its use …
The September 2018 issue of Pharmafocus is available to read online now!
September 3, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, AstraZeneca, Cancer, Iraw, J&J, JJ, Pfizer, Roche, UK, brexit, drug safety, pharma, pharmacovigilance
The new September edition of Pharmafocus is now live and available to read online. We’re entering the final stretch as …
NHS scraps restriction on availability of J&J’s Imbruvica in leukaemia patients
August 10, 2018Medical Communications, Sales and Marketing Cancer, J&J, JJ, Johnson & Johnson, NHS, NICE, UK, imbruvica, leukaemia, pharma
The NHS has dropped a controversial restriction preventing leukaemia patients from accessing Johnson & Johnson’s tyrosine kinase inhibitor Imbruvica (ibrutinib), …
Lawsuit alleges pharma giants funded terror in Iraq
August 2, 2018Business Services, Medical Communications, Sales and Marketing AstraZeneca, Iraq War, J&J, JJ, Litigation, Roche, corruption, terrorism
The United States Justice Department is investigating claims that major pharmaceutical and medical device companies were aware that supplies that …
Top Ten most popular articles on Pharmafile.com this week
July 27, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, China, GSK, Gilead, J&J, JJ, Pfizer, Remicade, Roche, antimicrobial resistance, biosimilar, pharma, pricing, viagra
With the UK in the grip of a record-breaking heatwave, it’s hard to focus on much else over here, but …
Top Ten most popular articles on Pharmafile.com this week
July 20, 2018Medical Communications GSK, ICR, J&J, JJ, Novartis, Trump, brexit, top 10
As Brexit negotions have hit a stalemate this week, the United Kingdom’s exit from the European Union has hit the …
J&J stops Invokana trial early after success in kidney disease and type 2 diabetes
July 17, 2018Manufacturing and Production, Research and Development J&J, JJ, Janssen, Johnson & Johnson, invokana, kidney disease, pharma, renal, type 2 diabetesm diabetes
Johnson & Johnson and research arm Janssen have taken the decision to terminate a Phase 3 trial evaluating the efficacy …
J&J ordered to pay $4.68 billion to talc-powder plaintiffs
July 13, 2018Medical Communications J&J, JJ, Johnson and Johnson, legal, talc powder
A Missouri jury has ordered the New Jersey-based healthcare company Johnson and Johnson to pay $4.69 billion to 22 women …
Missouri appeals court overturns $55m J&J verdict
July 6, 2018Medical Communications, Sales and Marketing Cancer, J&J, JJ, Litigation, appeal, pharma
A $55 million verdict against the multinational pharmaceutical company Johnson & Johnson has been overturned by an appeals court in …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
